The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-Analysis

Advances in Therapy

Volumn 34, Issue 3, 2017, Pages 611-619

  Danyliv, Andriy ^a   Glanville, Julie ^d   McCool, Rachael ^d   Ferreira, Alberto ^b   Skelly, Adrian ^b   Jacob, Ruth Pulikottil ^c  

^a Novartis Ireland Limited   (Ireland)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Novartis Pharmaceuticals UK Limited   (United Kingdom)

^d UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Aflibercept; Neovascular age related macular degeneration; Network meta analysis; Ophthalmology; Ranibizumab; Systematic review; Treat and extend; Vascular endothelial growth factor inhibitors

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

AGE RELATED MACULAR DEGENERATION; BEST CORRECTED VISUAL ACUITY; CLINICAL EFFECTIVENESS; HUMAN; META ANALYSIS; REVIEW; SYSTEMATIC REVIEW; VISION; AGED; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG MONITORING; EUROPE; METABOLISM; PATHOPHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME; VISUAL ACUITY; WET MACULAR DEGENERATION;

AGED; ANGIOGENESIS INHIBITORS; DRUG MONITORING; EUROPE; HUMANS; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 85012225011     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-017-0484-0     Document Type: Review

References (28)

1. Congdon N, O’Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122(4):477–85.
2. Pascolini D, Mariotti SP, Pokharel GP, et al. 2002 Global update of available data on visual impairment: a compilation of population-based prevalence studies. Ophthalmic Epidemiol. 2004;11(2):67–115.
3. Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–16.
4. Bunce C, Xing W, Wormald R. Causes of blind and partial sight certifications in England and Wales: April 2007–March 2008. Eye. 2010;24(11):1692–9.
5. Menon G, Walters G. New paradigms in the treatment of wet AMD: the impact of anti-VEGF therapy. Eye. 2009;23(Suppl 1):S1–7.
6. Owen CG, Jarrar Z, Wormald R, Cook DG, Fletcher AE, Rudnicka AR. The estimated prevalence and incidence of late stage age related macular degeneration in the UK. Br J Ophthalmol. 2012;96(5):752–6.
7. Wong TY, Liew G, Mitchell P. Clinical update: new treatments for age-related macular degeneration. Lancet. 2007;370(9583):204–6.
8. Bressler NM, Doan QV, Varma R, et al. Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-Hispanic white population in the United States with age-related macular degeneration. Arch Ophthalmol. 2011;129(6):709–17.
9. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012;379(9827):1728–38.
10. European Medicines Agency (EMA). Lucentis 10 mg/ml solution for injection. Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000715/WC500043546.pdf. Accessed 11 Feb 2016. 2009.
11. European Medicines Agency (EMA). Eylea 40 mg/ml solution for injection in pre-filled syringe. Summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002392/WC500135815.pdf. Accessed Feb 2016. 2012.
12. Berg K, Hadzalic E, Gjertsen I, et al. Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the lucentis compared to avastin study treat-and-extend protocol: two-year results. Ophthalmology. 2016;123(1):51–9.
13. Berg K, Pedersen TR, Sandvik L, Bragadottir R. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology. 2015;122(1):146–52.
14. Wykoff CC, Croft DE, Brown DM, et al. Prospective trial of treat-and-extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results. Ophthalmology. 2015;122(12):2514–22.
15. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331(7521):897–900.
16. Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health. 2011;14(4):417–28.
17. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23(20):3105–24.
18. Hykin P, Chakravarthy U, Lotery A, McKibbin M, Napier J, Sivaprasad S. A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK. Clin Ophthalmol. 2016;10:87–96.
19. Hodgson R, Barata T, Fleetwood K, Edwards M, Glanville J. Indirect treatment comparison of lucentis for wet age related macular degeneration. York Health Economics Consortium, York. 2014
20. Fitzgerald A, Cikalo M, Sreekanta A, et al. Systematic review of the clinical effectiveness and safety of lucentis for wet age-related macular degeneration. York: York Health Economics Consortium; 2014
21. National Insititute for Health and Care Excellence. Final guidance on the use of ranibizumab and pegaptanib for the treatment of age-related macular degeneration (AMD). London: National Insititute for Health and Care Excellence; 2008 (press release).
22. Australian Pharmaceutical Benefits Advisory Committee Indirect Comparisons Working Group. Report of the Indirect Comparisons Working Group to the Pharmaceutical Benefits Advisory Committee: Assessing Indirect Comparisons. Canberra: Australian Department of Health and Ageing, Pharmaceutical Benefits Advisory Committee, 2009.
23. Dakin HA, Welton NJ, Ades AE, Collins S, Orme M, Kelly S. Mixed treatment comparison of repeated measurements of a continuous endpoint: an example using topical treatments for primary open-angle glaucoma and ocular hypertension. Stat Med. 2011;30(20):2511–35.
24. Ding Y, Fu H. Bayesian indirect and mixed treatment comparisons across longitudinal time points. Stat Med. 2013;32(15):2613–28.
25. London NJ, Fung AE, Dugel PU, et al. A Prospective evaluation of ranibizumab for retinal pigment epithelial detachments in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009;50(5):2379.
26. Moon E, et al. Monthly versus PRN ranibizumab for neovascular AMD: a randomized phase 2 open-label study. Invest Ophthalmol Vis Sci 2011;52(6):133.
27. Cameron C, Fireman B, Hutton B, et al. Network meta-analysis incorporating randomized controlled trials and non-randomized comparative cohort studies for assessing the safety and effectiveness of medical treatments: challenges and opportunities. Syst Rev. 2015;4:147.
28. Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046–56.